HIGHLIGHTS
- who: Ekaterina A. Bryushkova et al. from the Pirogov National Research Medical University, Russia, Shemyakin and Ovchinnikov have published the research work: Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study, in the Journal: PLOS ONE of August/24,/2022
- what: This study compares three therapies affecting linked inflammatory pathways. The aim of this study was to assess inflammatory markers and clinical outcomes in hospitalized, mild-to-moderate COVID-19 patients treated with the combination of one of the three agents: netakimab, tocilizumab, and baricitinib with standard of care . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.